Skip to main content
NASDAQ:TCON

TRACON Pharmaceuticals News Headlines

$6.16
+0.35 (+6.02 %)
(As of 05/14/2021 12:00 AM ET)
Add
Compare
Today's Range
$5.81
$6.19
50-Day Range
$5.67
$9.01
52-Week Range
$1.55
$12.20
Volume67,362 shs
Average Volume381,707 shs
Market Capitalization$95.49 million
P/E RatioN/A
Dividend YieldN/A
Beta2.02

Headlines

TRACON Pharmaceuticals (NASDAQ TCON) News Headlines Today

SourceHeadline
Zacks: Analysts Expect TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) to Announce -$0.34 Earnings Per ShareZacks: Analysts Expect TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) to Announce -$0.34 Earnings Per Share
americanbankingnews.com - May 14 at 12:18 AM
TRACON Pharmaceuticals updates on its recent ENVASARC clinical trial advancementsTRACON Pharmaceuticals updates on its recent ENVASARC clinical trial advancements
proactiveinvestors.com - May 10 at 8:19 PM
TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) to Post FY2025 Earnings of $3.13 Per Share, Jefferies Financial Group ForecastsTRACON Pharmaceuticals, Inc. (NASDAQ:TCON) to Post FY2025 Earnings of $3.13 Per Share, Jefferies Financial Group Forecasts
americanbankingnews.com - May 10 at 5:00 AM
TRACON Pharmaceuticals ends 1Q with $30.4M to fund its cancer drug trialsTRACON Pharmaceuticals ends 1Q with $30.4M to fund its cancer drug trials
proactiveinvestors.com - May 7 at 3:56 PM
TRACON Pharmaceuticals (NASDAQ:TCON) Releases Quarterly  Earnings ResultsTRACON Pharmaceuticals (NASDAQ:TCON) Releases Quarterly Earnings Results
americanbankingnews.com - May 6 at 9:18 PM
NA Proactive news snapshot: Mountain Valley MD, Zynerba Pharmaceuticals, TRACON Pharmaceuticals, Kainantu Resources, Ready Set Gold UPDATENA Proactive news snapshot: Mountain Valley MD, Zynerba Pharmaceuticals, TRACON Pharmaceuticals, Kainantu Resources, Ready Set Gold UPDATE
proactiveinvestors.com - May 5 at 8:47 PM
TRACON Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate UpdateTRACON Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update
au.finance.yahoo.com - May 5 at 8:47 PM
TRACON Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate UpdateTRACON Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update
finance.yahoo.com - May 5 at 8:47 PM
TRACON Pharmaceuticals Announces Appointment of Dongliang Zhuang, Ph.D. as Vice President of Statistics and BiometricsTRACON Pharmaceuticals Announces Appointment of Dongliang Zhuang, Ph.D. as Vice President of Statistics and Biometrics
finance.yahoo.com - May 3 at 12:52 PM
Cortexyme (NASDAQ:CRTX) versus TRACON Pharmaceuticals (NASDAQ:TCON) Financial AnalysisCortexyme (NASDAQ:CRTX) versus TRACON Pharmaceuticals (NASDAQ:TCON) Financial Analysis
americanbankingnews.com - May 2 at 8:16 AM
TRACON Pharmaceuticals (TCON) Scheduled to Post Earnings on WednesdayTRACON Pharmaceuticals (TCON) Scheduled to Post Earnings on Wednesday
americanbankingnews.com - April 29 at 8:52 AM
TRACON to Report First Quarter 2021 Financial Results and Company Highlights on May 5, 2021TRACON to Report First Quarter 2021 Financial Results and Company Highlights on May 5, 2021
finance.yahoo.com - April 28 at 1:06 PM
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating TRACON Pharmaceuticals, Inc. for Potential Breaches of Fiduciary Duty By Its Board of DirectorsSHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating TRACON Pharmaceuticals, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors
finance.yahoo.com - April 26 at 10:57 AM
-$0.32 EPS Expected for TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) This Quarter-$0.32 EPS Expected for TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) This Quarter
americanbankingnews.com - April 26 at 2:08 AM
TRACON Pharmaceuticals (NASDAQ:TCON) Stock Rating Upgraded by BTIG ResearchTRACON Pharmaceuticals (NASDAQ:TCON) Stock Rating Upgraded by BTIG Research
americanbankingnews.com - April 22 at 9:36 AM
TRACON Pharmaceuticals driving the development of targeted therapies for cancer via collaborationsTRACON Pharmaceuticals driving the development of targeted therapies for cancer via collaborations
proactiveinvestors.com - March 25 at 3:51 PM
TRACON Pharmaceuticals Announces Poster Presentation at the 2021 AACR Virtual Annual MeetingTRACON Pharmaceuticals Announces Poster Presentation at the 2021 AACR Virtual Annual Meeting
finance.yahoo.com - March 23 at 8:39 AM
TRACON Pharmaceuticals to Present at the Oppenheimer 31st Annual Healthcare ConferenceTRACON Pharmaceuticals to Present at the Oppenheimer 31st Annual Healthcare Conference
finance.yahoo.com - March 9 at 12:39 PM
TRACON Pharmaceuticals appoints pharma executive Dr Lisa Johnson-Pratt to its board of directorsTRACON Pharmaceuticals appoints pharma executive Dr Lisa Johnson-Pratt to its board of directors
proactiveinvestors.com - March 8 at 2:42 PM
TRACON Pharmaceuticals to Present at the H.C. Wainwright Global Life Sciences ConferenceTRACON Pharmaceuticals to Present at the H.C. Wainwright Global Life Sciences Conference
finance.yahoo.com - March 2 at 8:22 AM
Taking A Gander At Tracon PharmaceuticalsTaking A Gander At Tracon Pharmaceuticals
seekingalpha.com - March 1 at 9:38 AM
TRACON Pharmaceuticals Reports Fourth Quarter and Year-End 2020 Financial Results and Provides Corporate UpdateTRACON Pharmaceuticals Reports Fourth Quarter and Year-End 2020 Financial Results and Provides Corporate Update
finance.yahoo.com - February 25 at 6:27 PM
TRACON to Report Fourth Quarter and Full Year 2020 Financial Results and Company Highlights on February 25, 2021TRACON to Report Fourth Quarter and Full Year 2020 Financial Results and Company Highlights on February 25, 2021
finance.yahoo.com - February 18 at 9:24 AM
Thursday 1/28 Insider Buying Report: OVLY, TCONThursday 1/28 Insider Buying Report: OVLY, TCON
nasdaq.com - January 28 at 5:46 PM
TRACON says cancer drug envafolimab gets priority review from Chinese regulators, according to corporate partnersTRACON says cancer drug envafolimab gets priority review from Chinese regulators, according to corporate partners
proactiveinvestors.com - January 19 at 12:17 PM
TRACON Pharmaceuticals Announces Acceptance of the Envafolimab (KN035) NDA by the NMPA in China for Priority ReviewTRACON Pharmaceuticals Announces Acceptance of the Envafolimab (KN035) NDA by the NMPA in China for Priority Review
finance.yahoo.com - January 19 at 12:17 PM
TRACON Pharmaceuticals to Present at the H.C. Wainwright Virtual BioConnect 2021 ConferenceTRACON Pharmaceuticals to Present at the H.C. Wainwright Virtual BioConnect 2021 Conference
finance.yahoo.com - January 6 at 12:23 PM
TRACON Pharmaceuticals Announces Acceptance of the Envafolimab (KN035) NDA by the NMPA in China that was Submitted by its Corporate Partners Alphamab Oncology and 3D MedicinesTRACON Pharmaceuticals Announces Acceptance of the Envafolimab (KN035) NDA by the NMPA in China that was Submitted by its Corporate Partners Alphamab Oncology and 3D Medicines
finance.yahoo.com - December 30 at 8:16 AM
TRACON Pharmaceuticals enters into securities purchase agreement with existing investor, with aggregate gross proceeds expected to be $5.0MTRACON Pharmaceuticals enters into securities purchase agreement with existing investor, with aggregate gross proceeds expected to be $5.0M
proactiveinvestors.com - December 29 at 2:03 PM
TRACON Pharmaceuticals Announces $5.0 Million Registered Direct OfferingTRACON Pharmaceuticals Announces $5.0 Million Registered Direct Offering
finance.yahoo.com - December 29 at 9:02 AM
TRACON Pharmaceuticals says it is looking to raise aggregate gross proceeds of $8.8 million from a registered direct share offeringTRACON Pharmaceuticals says it is looking to raise aggregate gross proceeds of $8.8 million from a registered direct share offering
proactiveinvestors.com - December 22 at 2:35 PM
TRACON Pharmaceuticals Announces $8.8 Million Registered Direct OfferingTRACON Pharmaceuticals Announces $8.8 Million Registered Direct Offering
finance.yahoo.com - December 22 at 9:18 AM
TRACON Pharmaceuticals says first patient dosed in ENVASARC registration trial to treat soft-tissue sarcoma cancerTRACON Pharmaceuticals says first patient dosed in ENVASARC registration trial to treat soft-tissue sarcoma cancer
proactiveinvestors.com - December 10 at 3:12 PM
TRACON Pharmaceuticals Announces Dosing of First Patient in ENVASARC Pivotal TrialTRACON Pharmaceuticals Announces Dosing of First Patient in ENVASARC Pivotal Trial
finance.yahoo.com - December 10 at 3:12 PM
3 Biotech Stocks to Buy on First Vaccine Approval Optimism3 Biotech Stocks to Buy on First Vaccine Approval Optimism
finance.yahoo.com - December 3 at 3:57 PM
Is TRACON Pharmaceuticals (TCON) A Good Stock To Buy Now?Is TRACON Pharmaceuticals (TCON) A Good Stock To Buy Now?
finance.yahoo.com - November 30 at 5:35 PM
TRACON says publication of clinical data in Cancer Cell journal provides molecular insight into TRC102TRACON says publication of clinical data in Cancer Cell journal provides molecular insight into TRC102
proactiveinvestors.com - November 24 at 9:24 PM
TRACON Announces Publication in Cancer Cell of Clinical Data that Provides Molecular Insight into the Mechanism of Action of TRC102 and Patient Populations Most Likely to Respond to TreatmentTRACON Announces Publication in Cancer Cell of Clinical Data that Provides Molecular Insight into the Mechanism of Action of TRC102 and Patient Populations Most Likely to Respond to Treatment
finance.yahoo.com - November 23 at 2:06 PM
TRACONs partners submit new drug application for approval of envafolimab to the NMPA in ChinaTRACON's partners submit new drug application for approval of envafolimab to the NMPA in China
proactiveinvestors.com - November 21 at 8:50 PM
TRACON says envafolimab NDA submitted for approval by its partners to the NMPA in ChinaTRACON says envafolimab NDA submitted for approval by its partners to the NMPA in China
proactiveinvestors.com - November 16 at 5:08 PM
Tracon Pharma files China application for envafolimab in solid tumorsTracon Pharma files China application for envafolimab in solid tumors
seekingalpha.com - November 16 at 5:08 PM
TRACON Pharmaceuticals Announces Submission for Approval of Envafolimab (KN035) with the NMPA in China by its Corporate Partners Alphamab Oncology and 3D MedicinesTRACON Pharmaceuticals Announces Submission for Approval of Envafolimab (KN035) with the NMPA in China by its Corporate Partners Alphamab Oncology and 3D Medicines
finance.yahoo.com - November 16 at 12:08 PM
TRACON Pharmaceuticals strengthens its cash position in 3Q to fund operations into 2022TRACON Pharmaceuticals strengthens its cash position in 3Q to fund operations into 2022
proactiveinvestors.com - November 11 at 4:27 AM
TRACON Pharmaceuticals, Inc. (TCON) CEO Charles Theuer on Q3 2020 Results - Earnings Call TranscriptTRACON Pharmaceuticals, Inc. (TCON) CEO Charles Theuer on Q3 2020 Results - Earnings Call Transcript
seekingalpha.com - November 11 at 4:27 AM
TRACON Pharmaceuticals, Inc. to Host Earnings CallTRACON Pharmaceuticals, Inc. to Host Earnings Call
finance.yahoo.com - November 10 at 6:11 PM
TRACON Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Corporate UpdateTRACON Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Corporate Update
finance.yahoo.com - November 10 at 6:11 PM
TRACON to Report Third Quarter 2020 Financial Results and Company Highlights on November 10, 2020TRACON to Report Third Quarter 2020 Financial Results and Company Highlights on November 10, 2020
finance.yahoo.com - November 3 at 9:16 AM
NA Proactive news snapshot: Revive Therapeutics, KULR Technology, Lexaria Bioscience, TRACON Pharmaceuticals UPDATENA Proactive news snapshot: Revive Therapeutics, KULR Technology, Lexaria Bioscience, TRACON Pharmaceuticals UPDATE
proactiveinvestors.com - October 26 at 11:20 PM
TRACON wins FDA Orphan Drug status for TRC102 in malignant gliomaTRACON wins FDA Orphan Drug status for TRC102 in malignant glioma
proactiveinvestors.com - October 26 at 11:20 PM
Tracons TRC102 an Orphan Drug in U.S. for malignant gliomaTracon's TRC102 an Orphan Drug in U.S. for malignant glioma
seekingalpha.com - October 26 at 1:08 PM
This page was last updated on 5/15/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.